I In nt tr ro od du uc ct ti io on n. . Recently, calcineurin has been shown to induce cardiac hypertrophy. Mitogenactivated protein kinases (MAPK), including the extracellular-signal regulated kinases (ERK), the c-Jun NH2-terminal kinases (JNK) and the p38 MAPK (p38), have also been shown to be important in the transduction of trophic signals. The objective of this study was to investigate possible cross-talk between calcineurin and MAPK pathways in controlling renovascular hypertension-induced cardiac hypertrophy. M Me et th ho od ds s. . Renovascular hypertension was induced by the two kidney-one clip method. The left ventricular weight (LVW) and the ratio of LVW to tibial length were measured to assay the degree of cardiac hypertrophy. Calcineurin activity and MAPK mRNA expression were measured. R Re es su ul lt ts s. . In the left ventricle of rats with renovascular hypertension, calcineurin activity and JNK mRNA expression were increased while cardiac hypertrophy developed. Treatment with the calcineurin blocker ciclosporin A induced calcineurin inhibition and regression of cardiac hypertrophy with an improvement of cardiac diastolic function. The treatment also resulted in down-regulation of JNK mRNA expression, but the mRNA expressions of ERK and p38 were unchanged. C Co on nc cl lu us si io on ns s. . There is cross-talk between the calcineurin and JNK pathway in controlling renovascular hypertension-induced cardiac hypertrophy. Inhibition of the calcineurin and JNK pathways may be the basis of reversal of cardiac hypertrophy by calcineurin blockers.
Introduction
Although cardiac hypertrophy initially represents an adaptive response that temporarily augments or maintains cardiac output, sustained cardiac hypertrophy is considered a leading cause of the development of heart failure and sudden death in humans. 1, 2 For this reason, it is very important to understand the underlying mechanism of cardiac hypertrophy and prevent or treat it. Cardiac hypertrophy can be induced by haemodynamic overload, ischemic disease, neurohumoral factors, or intrinsic defects in cardiac structural protein genes. Although some extrinsic and intrinsic factors that determine cardiac hypertrophy have been identified, a unifying hypothesis that explains how multiple diverse stimuli are transduced into the final hypertrophic response remains elusive.
Calcium plays an important role in various cellular processes, such as cell growth and survival, 3 including cardiac hypertrophy. 4 Calcineurin (CaN) is a calcium/calmodulin-activated cytoplasmic protein phosphatase that transduces hypertropic stimuli to regulate transcriptional control of myocyte transformation. Recently, several groups have investigated the importance of CaN signalling in both in vitro and in vivo hypertrophy models, [5] [6] [7] [8] [9] and demonstrated that CaN inhibitors, such as ciclosporin A (CsA) or FK506, prevent cardiac hypertrophy. Cardiac hypertrophy has also been associated with alterations in many intracellular signal transduction pathways, such as the three main branches of the mitogen-activated protein kinases (MAPK) signalling cascade, namely the extracellular-signal regulated kinases (ERK), the c-Jun NH2-terminal kinases (JNK) and the p38 MAPK (p38). A large number of in vitro and in vivo studies has identified important roles of the three branches of the MAPK signalling pathway in cardiomyocyte or cardiac hypertrophy. [10] [11] [12] [13] However, the researches about MAPK have been performed mostly at the activity level, and some at the protein expression level, while there is little research at the gene expression level. Moreover, CaN and MAPK are both important signalling pathways that mediate cardiac hypertrophy. Hence, their relationship needs further research.
In the present study, we investigated, in a rat model of renovascular hypertension, whether there was cross-talk between the CaN and MAPK pathways at the mRNA expression level. The results demonstrated that the CaN inhibitor CsA induced the regression of cardiac hypertrophy in rats with renovascular hypertension. In addition, the CaN blocker was also shown to inhibit the up-regulation of JNK mRNA expression in the cardiac tissue, suggesting cross-talks between CaN and JNK pathways in renovascular hypertensive rats.
Methods

Animals
Male Sprague-Dawley rats weighing 210±25 g were obtained from the animal centre of Nanjing Medical University (China). All experimental procedures involving animals were conducted as per Institutional Animal Care guidelines and approved ethically by the Administration Committee of experimental animals, Jiangsu Province, China. Rats were anaesthetised using ketamine hydrochloride (50 mg/kg). Two kidney-one clip (2K1C) renovascular hypertension was induced by placing a silver clip (internal diameter 0.25 mm) around the left renal artery through a flank incision. The right kidney was left undisturbed. Sham-operated rats underwent the same experimental procedure, but no clip was placed. Rats were maintained on sterile tap water and a regular rodent diet ad libitum. Two months after clipping, when cardiac hypertrophy had already developed, the rats were randomly divided into two groups: one group was given placebo (0.9% saline) as a control, one group was administered CsA (20 mg/kg body weight daily; Novartis, Switzerland). All treatments were started at two months after clipping, and continued until three months.
Haemodynamic measurement
At two or three months after clipping, the rats were anaesthetised by intraperitoneal injection of ketamine hydrochloride (50 mg/kg). A 'home-made' catheter was inserted through the right carotid artery into the aorta to determine systolic blood pressure (SBP). The catheter was subsequently advanced further into the left ventricle (LV). Then Vmax, LV end-diastolic pressure (LVEDP) and time constant (T) were recorded using a computer data acquisition workstation (BL410 biopsy laboratory system, China).
Semi-quantitative reverse transcriptase-polymerase chain reaction (RT-PCR)
Total RNA was extracted from the LV sample using the modified single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Complementary DNA was then synthesised from 2 µg of total RNA with an oligo(dT) [12] [13] [14] [15] [16] [17] [18] primer and reverse transcriptase. PCR was performed with primers specific for ERK, JNK, p38 and GAPDH mRNAs (table 1), using GAPDH mRNA as an internal standard. The PCR products of each target gene were verified by sequencing.
Assay of CaN activity
The activity of CaN in lysates of LV samples was determined as described previously 14 with a small modification. Tissue was homogenised in a buffer containing 50 mmol/L Tris-HCl (pH 7.5), 0.5 mmol/L dithiothreitol and protease inhibitors, and cell debris was removed by centrifugation. 
Statistical analysis
All data are expressed as the mean±SEM. Twoway ANOVA and post hoc q test were carried out for multiple comparisons among groups. A value of p<0.05 was considered statistically significant.
Results
Effect of CsA on the reversal of cardiac hypertrophy
Two months after 2K1C, the rats had a blood pressure that was 1.6 times greater than that of age-matched sham-operated rats, and the elevation of blood pressure was also observed in untreated rats at three months after clipping (untreated three-month 2K1C rats). Furthermore, blood pressure was not affected by the CsA treatment, there was no significant difference in blood pressure between the CsA-treated 2K1C rats and the untreated 2K1C rats (figure 1).
The LV weight (LVW) of untreated three-month 2K1C rats was significantly higher than that of age-matched sham-operated rats. CsA treatment strongly attenuated the increase in LVW of 2K1C rats (figure 2). Since treatment with CsA decreased the body weight (BW), there was no significant difference in the LVW-to-BW ratio (LVW/BW) between CsA-treated 2K1C rats and the untreated 2K1C rats (data not shown). Because tibial length (TL) is a better internal control than BW to assess relative size of organs, including the heart, 15 we used TL as the internal control instead of BW. The ratio of LVW-to-TL (LVW/TL) of untreated three-month 2K1C rats was significantly higher than that of age-matched sham-operated rats. Treatment with CsA for one month significantly attenuated the increase in LVW/TL in 2K1C rats (figure 2). Moreover, the LVW and LVW/TL of CsAtreated three-month 2K1C rats were significantly less than those of untreated two-month 2K1C rats (figure 2), suggesting that the CsA treatment induced the regression of cardiac hypertrophy.
Effects of CsA on CaN activation
CsA-mediated reversal of cardiac hypertrophy in 2K1C rats suggests that CaN is involved in the long-term maintenance of cardiac hypertrophy in this model. To further establish an association between CaN and cardiac hypertrophy in 2K1C rats, we measured CaN activity.
CaN activity in the LV samples of untreated two-or three-month 2K1C rats was increased by 39% or 24%, respectively, compared with that of age-matched sham-operated rats, and this 
Figure 1
Systolic blood pressure measured in aorta. The blood pressure of untreated 2-or 3-month 2K1C rats was higher than that of age-matched sham rats. There was no significant difference in blood pressure between untreated 3-month 2K1C rats and CsA-treated rats. Data are shown as mean±SEM. * p<0.05, versus 2-month sham rats; # p<0.05, versus 3-month sham rats; NS means no significance. increase was suppressed completely by treatment with CsA ( figure 3 ).
Effects of CsA on the expression of MAPK mRNA
Compared with age-matched sham-operated rats, there was a trend of up-regulation in ERK1 mRNA expression and a trend of down-regulation in p38 mRNA expression in untreated two-or threemonth 2K1C rats. However, these differences were not statistically significant. There were no significant changes in the ERK2 mRNA expression throughout the experiment between sham and 2K1C rats. Moreover, CsA administration starting from two months after clipping did not significantly change the ERK1, ERK2 and p38 mRNA expression (figure 4).
Compared with age-matched sham-operated rats, the JNK mRNA expression level in the LV samples of untreated two-or three-month 2K1C rats was increased. Furthermore, the increase was significantly attenuated by the administration of CsA (figure 4).
Effect of CsA on cardiac function in vivo
Three months after operation, LV systolic function, measured as Vmax, was similar between sham-operated rats (Vmax=242.2±6.9/ms, n=6) and untreated 2K1C rats (Vmax=237.3±18.2/ms, n=9). The study also revealed preservation of systolic function in CsA-treated 2K1C rats (Vmax=227.2±13.2/ms, n=9), despite the reversal of cardiac hypertrophy (figure 5).
LV end-diastolic pressure (LVEDP) and time constant (T) were determined by using haemodynamic measurements to evaluate LV diastolic function. It was found that LVEDP was elevated and T was prolonged in untreated two-or three-month 2K1C rats as compared with age-matched shamoperated rats respectively, but these abnormalities were not evident in CsA-treated three-month 2K1C rats, and there was no significant difference between CsA-treated 2K1C rats and shamoperated rats. These results suggest the improvement of cardiac diastolic function with CsA treatment ( figure 6 ).
Discussion
The renin-angiotensin system is crucial for the maintenance of blood pressure, fluid and sodium homeostasis, and also plays a role in the pathogenesis of hypertension. In the two kidney-one clip model of renovascular hypertension, one renal artery is constricted to reduce renal perfusion, and the other kidney remains untouched. In response to low renal arterial pressure, the plasma renin concentration is rapidly increased and then the renin-angiotensin-aldosterone system is activated, resulting in chronic elevation of blood pressure and subsequent cardiac hypertrophy.
CaN, as a calcium/calmodulin-activated protein phosphatase, is typically activated by calcium bound to calmodulin. Since Molkentin et al. in 1998 found a CaN-dependent transcriptional pathway for cardiac hypertrophy, the controversy over the importance of CaN signalling in clinically relevant forms of hypertrophy persists. 17 Now the involvement of CaN in hypertrophic signalling has been demonstrated using a variety of approaches that include both cell culture and intact animal models. [5] [6] [7] [8] [9] Our study found that in the 2K1C rat heart, CaN activity was increased and cardiac hypertrophy was induced. Treatment of 2K1C rats with the CaN inhibitor CsA from two months after clipping to three months inhibited the activation of CaN in the heart and induced the regression of cardiac hypertrophy. These results suggest that CaN is involved in the development of renovascular hypertension-induced cardiac hypertrophy.
In addition to the CaN pathway, there are other signalling cascades involved in the development and maintenance of myocardial hypertrophy, such as mitogen-activated protein kinases (including ERK, JNK and p38), protein kinase C and protein kinase A. There is an integrated model of signal transduction in the heart such that multiple pathways are necessary for timely and effective hypertrophy. 17 In order to further investigate the mechanism by which CsA induced the regression of cardiac hypertrophy, we studied the relationship between CaN and MAPK. The expression of JNK mRNA was increased in the hearts of untreated two-or three-month 2K1C rats, and the CaN blocker resulted simultaneously in the reversal of cardiac hypertrophy and down-regulation of JNK mRNA expression. Taken together, these results suggest that there is cross-talk between CaN and JNK pathways at the level of mRNA expression. This is consistent with recently published data showing that a CaN blocker prevents JNK activation at the level of protein expression in aortic banded as well as in 2K1C rats. 18 It has recently been reported that CaN-NFAT and MEK1-ERK1/2 pathways constitute a codependent signalling module in cardiomyocytes that coordinately regulates the growth response. 19 Carabin is a negative feedback inhibitor of the CaN signalling pathway that also mediates cross-talk between CaN and Ras. 20 Therefore, inhibition of CaN and JNK signalling pathways may be the basis of the 
Figure 4
A: Representative example of MAPK (including ERK1 and ERK2, JNK and p38) transcripts. Control PCR was performed with GAPDH. Sham 2M, 2-month sham rats; 2K1C 2M, 2-month 2K1C rats; Sham 3M, 3-month sham rats; 2K1C 3M, 3-month 2K1C rats; 2K1C+CsA, CsA treated 2K1C rats. B: The level of MAPK mRNA expression shown as bar graph. There were no significant differences in the mRNA expression of ERK1, ERK2 and p38 among these groups. However, the JNK mRNA level increased in 2-and 3-months 2K1C rats compared with age-matched sham rats, and the increase was significantly attenuated by the administration of CsA. Data are shown as mean±SEM. * p<0.05, versus 2-month sham rats; # p<0.05, versus 3-month sham rats; † p<0.05, versus 3-month 2K1C rats. reversal of cardiac hypertrophy by the CaN inhibitor CsA.
Our study also indicated that LV systolic performance was preserved despite the reversal of cardiac hypertrophy in renovascular hypertensive rats. This finding is consistent with that reported by Hill et al. 21 for aortic banded mice, where the underlying mechanism was considered to be associated with a sustained Anrep effect. The preservation of systolic function suggests that hypertrophy is not required for maintenance of systolic performance. In contrast, the improvement of cardiac diastolic function by CsA treatment, as shown in this study, might be attributed to the CsA-induced regression of cardiac hypertrophy. This result is consistent with that reported by Sakata et al. 22 for Dahl salt-sensitive rats. The regression of cardiac hypertrophy should account for the improvement in LV chamber compliance and the decrease in myocardial stiffness. 22 Our study does have certain limitations. First, the relevant protein level and activity of JNK were not measured. However, Murat et al. 18 examined the JNK activity in 2K1C mice and found that cardiac JNK activity was elevated in untreated 2K1C mice and decreased in CsA-treated 2K1C mice. This result is consistent with the JNK changes at the mRNA expression level in our study. Secondly, we measured CaN activity as the only parameter for the determination of the activity of the CaN signalling pathway. Modulatory calcineurin-interacting protein (MCIP) is an endogenous regulator of hypertrophic signalling in the heart that does not prevent normal heart growth and development, and it is accepted that the mRNA level of MCIP is a sensitive indicator of CaN activity in lung and heart. 23 An increase in MCIP1.4 mRNA levels is a commonly used parameter for the determination of the activity of CaN signalling. It would have been preferable if we had also measured MCIP1.4 mRNA levels in our study.
In conclusion, the results of this study suggest that there are cross-talks between CaN and JNK pathway in controlling renovascular hypertension-induced cardiac hypertrophy. The inhibition of CaN and JNK pathways may be the basis of reversal of cardiac hypertrophy by CaN blockers. 
Figure 5
Cardiac systolic function (measured as Vmax) detected by haemodynamic measurement for sham, 2K1C, and 2K1C +CsA rats. There was no significant difference in Vmax among these groups.
Figure 6
The Effect of CsA on LV diastolic function (measured as LVEDP and Time Constant) in vivo. * p<0.05, versus 2-month sham rats; # p<0.05, versus 3-month sham rats; † p<0.05, versus 3-month 2K1C rats.
